Standout Papers

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlle... 2024 202659
  1. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials (2024)
    Alexa B. Kimball, Gregor B. E. Jemec et al. The Lancet

Immediate Impact

66 standout
Sub-graph 1 of 24

Citing Papers

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
The immunostimulatory nature of mRNA lipid nanoparticles
2024 Standout
1 intermediate paper

Works of Robert Rolleri being referenced

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
2021
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
2014

Author Peers

Author Last Decade Papers Cites
Robert Rolleri 232 238 237 29 576
Richard Ahn 130 193 124 25 641
Eugenia Shmidt 221 56 341 30 686
Esther García-Planella 143 72 265 26 561
Siddhant Yadav 231 56 274 22 545
Giammarco Mocci 129 30 345 38 692
Pauline Rivière 314 35 293 45 739
Santiago Jiménez 157 34 162 38 610
Philippe Godeberge 293 38 292 23 659
Richard D. Baughman 63 247 126 30 654
Seona Park 155 28 193 18 535

All Works

Loading papers...

Rankless by CCL
2026